Glucagon‑like  ||| S:0 E:14 ||| NNP
peptide‑1  ||| S:14 E:24 ||| NNP
protects  ||| S:24 E:33 ||| VBZ
cardiomyocytes  ||| S:33 E:48 ||| VBN
from  ||| S:48 E:53 ||| IN
advanced  ||| S:53 E:62 ||| JJ
oxidation  ||| S:62 E:72 ||| JJ
protein  ||| S:72 E:80 ||| NN
product‑induced  ||| S:80 E:96 ||| CD
apoptosis  ||| S:96 E:106 ||| NN
via  ||| S:106 E:110 ||| IN
the  ||| S:110 E:114 ||| DT
PI3K ||| S:114 E:118 ||| FW
/ ||| S:118 E:119 ||| FW
Akt ||| S:119 E:122 ||| FW
/ ||| S:122 E:123 ||| FW
Bad  ||| S:123 E:127 ||| FW
signaling  ||| S:127 E:137 ||| FW
pathway  ||| S:137 E:145 ||| FW
Cardiomyocyte  ||| S:145 E:159 ||| FW
apoptosis  ||| S:159 E:169 ||| FW
is  ||| S:169 E:172 ||| VBZ
a  ||| S:172 E:174 ||| DT
major  ||| S:174 E:180 ||| JJ
event  ||| S:180 E:186 ||| NN
in  ||| S:186 E:189 ||| IN
the  ||| S:189 E:193 ||| DT
pathogenesis  ||| S:193 E:206 ||| NN
of  ||| S:206 E:209 ||| IN
diabetic  ||| S:209 E:218 ||| JJ
cardiomyopathy ||| S:218 E:232 ||| NN
.  ||| S:232 E:234 ||| .
Currently ||| S:234 E:243 ||| RB
,  ||| S:243 E:245 ||| ,
no  ||| S:245 E:248 ||| DT
single  ||| S:248 E:255 ||| JJ
effective  ||| S:255 E:265 ||| JJ
treatment  ||| S:265 E:275 ||| NN
for  ||| S:275 E:279 ||| IN
diabetic  ||| S:279 E:288 ||| JJ
cardiomyopathy  ||| S:288 E:303 ||| NN
exists ||| S:303 E:309 ||| VBZ
.  ||| S:309 E:311 ||| .
The  ||| S:311 E:315 ||| DT
present  ||| S:315 E:323 ||| JJ
study  ||| S:323 E:329 ||| NN
investigated  ||| S:329 E:342 ||| VBN
whether  ||| S:342 E:350 ||| IN
advanced  ||| S:350 E:359 ||| JJ
oxidative  ||| S:359 E:369 ||| JJ
protein  ||| S:369 E:377 ||| NN
products  ||| S:377 E:386 ||| NNS
( ||| S:386 E:387 ||| -LRB-
AOPPs ||| S:387 E:392 ||| NNP
)  ||| S:392 E:394 ||| -RRB-
have  ||| S:394 E:399 ||| VBP
a  ||| S:399 E:401 ||| DT
detrimental  ||| S:401 E:413 ||| JJ
role  ||| S:413 E:418 ||| NN
in  ||| S:418 E:421 ||| IN
the  ||| S:421 E:425 ||| DT
survival  ||| S:425 E:434 ||| NN
of  ||| S:434 E:437 ||| IN
cardiomyocytes  ||| S:437 E:452 ||| NN
and  ||| S:452 E:456 ||| CC
if  ||| S:456 E:459 ||| IN
glucagon‑like  ||| S:459 E:473 ||| NNP
peptide‑1  ||| S:473 E:483 ||| NNP
( ||| S:483 E:484 ||| -LRB-
GLP‑1 ||| S:484 E:489 ||| NNP
)  ||| S:489 E:491 ||| -RRB-
exerts  ||| S:491 E:498 ||| VBZ
a  ||| S:498 E:500 ||| DT
cardioprotective  ||| S:500 E:517 ||| JJ
effect  ||| S:517 E:524 ||| NN
under  ||| S:524 E:530 ||| IN
these  ||| S:530 E:536 ||| DT
circumstances ||| S:536 E:549 ||| NNS
.  ||| S:549 E:551 ||| .
The  ||| S:551 E:555 ||| DT
present  ||| S:555 E:563 ||| JJ
study  ||| S:563 E:569 ||| NN
also  ||| S:569 E:574 ||| RB
aimed  ||| S:574 E:580 ||| VBN
to  ||| S:580 E:583 ||| TO
determine  ||| S:583 E:593 ||| VB
the  ||| S:593 E:597 ||| DT
underlying  ||| S:597 E:608 ||| JJ
mechanisms ||| S:608 E:618 ||| NNS
.  ||| S:618 E:620 ||| .
H9c2 cells  ||| S:620 E:631 ||| NNP
were  ||| S:631 E:636 ||| VBD
exposed  ||| S:636 E:644 ||| VBN
to  ||| S:644 E:647 ||| TO
increasing  ||| S:647 E:658 ||| VBG
concentrations  ||| S:658 E:673 ||| NNS
of  ||| S:673 E:676 ||| IN
AOPPs  ||| S:676 E:682 ||| JJ
in  ||| S:682 E:685 ||| IN
the  ||| S:685 E:689 ||| DT
presence  ||| S:689 E:698 ||| NN
or  ||| S:698 E:701 ||| CC
absence  ||| S:701 E:709 ||| NN
of  ||| S:709 E:712 ||| IN
GLP‑1 ||| S:712 E:717 ||| NNP
,  ||| S:717 E:719 ||| ,
and  ||| S:719 E:723 ||| CC
the  ||| S:723 E:727 ||| DT
viability  ||| S:727 E:737 ||| NN
and  ||| S:737 E:741 ||| CC
apoptotic  ||| S:741 E:751 ||| JJ
rate  ||| S:751 E:756 ||| NN
were  ||| S:756 E:761 ||| VBD
detected  ||| S:761 E:770 ||| VBN
using  ||| S:770 E:776 ||| VBG
a  ||| S:776 E:778 ||| DT
cell  ||| S:778 E:783 ||| NN
counting  ||| S:783 E:792 ||| VBG
kit‑8 assay  ||| S:792 E:804 ||| NNP
and  ||| S:804 E:808 ||| CC
flow  ||| S:808 E:813 ||| NN
cytometry ||| S:813 E:822 ||| NN
,  ||| S:822 E:824 ||| ,
respectively ||| S:824 E:836 ||| RB
.  ||| S:836 E:838 ||| .
In  ||| S:838 E:841 ||| IN
addition ||| S:841 E:849 ||| NN
,  ||| S:849 E:851 ||| ,
a  ||| S:851 E:853 ||| DT
phosphatidylinositol‑4,5‑bisphosphate 3‑kinase  ||| S:853 E:900 ||| NNP
( ||| S:900 E:901 ||| -LRB-
PI3K ||| S:901 E:905 ||| NNP
)  ||| S:905 E:907 ||| -RRB-
inhibitor ||| S:907 E:916 ||| NN
,  ||| S:916 E:918 ||| ,
LY294002 ||| S:918 E:926 ||| NNP
,  ||| S:926 E:928 ||| ,
was  ||| S:928 E:932 ||| VBD
employed  ||| S:932 E:941 ||| VBN
to  ||| S:941 E:944 ||| TO
illustrate  ||| S:944 E:955 ||| VB
the  ||| S:955 E:959 ||| DT
mechanism  ||| S:959 E:969 ||| NN
of  ||| S:969 E:972 ||| IN
the  ||| S:972 E:976 ||| DT
antiapoptotic  ||| S:976 E:990 ||| JJ
effect  ||| S:990 E:997 ||| NN
of  ||| S:997 E:1000 ||| IN
GLP‑1 ||| S:1000 E:1005 ||| CD
.  ||| S:1005 E:1007 ||| .
The  ||| S:1007 E:1011 ||| DT
expression  ||| S:1011 E:1022 ||| NN
levels  ||| S:1022 E:1029 ||| NNS
of  ||| S:1029 E:1032 ||| IN
the  ||| S:1032 E:1036 ||| DT
apoptotic‑associated  ||| S:1036 E:1057 ||| CD
proteins ||| S:1057 E:1065 ||| NNS
,  ||| S:1065 E:1067 ||| ,
Akt ||| S:1067 E:1070 ||| NNP
,  ||| S:1070 E:1072 ||| ,
B‑cell  ||| S:1072 E:1079 ||| CD
lymphoma  ||| S:1079 E:1088 ||| NNS
( ||| S:1088 E:1089 ||| -LRB-
Bcl ||| S:1089 E:1092 ||| NNP
) ||| S:1092 E:1093 ||| -RRB-
‑2 ||| S:1093 E:1095 ||| NNP
,  ||| S:1095 E:1097 ||| ,
Bcl‑2‑associated  ||| S:1097 E:1114 ||| CD
death  ||| S:1114 E:1120 ||| NN
promoter  ||| S:1120 E:1129 ||| NN
( ||| S:1129 E:1130 ||| -LRB-
Bad ||| S:1130 E:1133 ||| NNP
) ||| S:1133 E:1134 ||| -RRB-
,  ||| S:1134 E:1136 ||| ,
Bcl‑2‑associated X protein  ||| S:1136 E:1163 ||| NNP
( ||| S:1163 E:1164 ||| -LRB-
Bax ||| S:1164 E:1167 ||| NNP
)  ||| S:1167 E:1169 ||| -RRB-
and  ||| S:1169 E:1173 ||| CC
caspase‑3 were  ||| S:1173 E:1188 ||| RB
measured  ||| S:1188 E:1197 ||| VBN
by  ||| S:1197 E:1200 ||| IN
western  ||| S:1200 E:1208 ||| JJ
blotting ||| S:1208 E:1216 ||| NN
.  ||| S:1216 E:1218 ||| .
It  ||| S:1218 E:1221 ||| PRP
was  ||| S:1221 E:1225 ||| VBD
revealed  ||| S:1225 E:1234 ||| VBN
that  ||| S:1234 E:1239 ||| IN
GLP‑1 significantly  ||| S:1239 E:1259 ||| CD
attenuated  ||| S:1259 E:1270 ||| CD
AOPP‑induced  ||| S:1270 E:1283 ||| CD
cell  ||| S:1283 E:1288 ||| NN
toxicity  ||| S:1288 E:1297 ||| NN
and  ||| S:1297 E:1301 ||| CC
apoptosis ||| S:1301 E:1310 ||| NN
.  ||| S:1310 E:1312 ||| .
AOPPs  ||| S:1312 E:1318 ||| NNP
inactivated  ||| S:1318 E:1330 ||| VBD
the  ||| S:1330 E:1334 ||| DT
phosphorylation  ||| S:1334 E:1350 ||| NN
of  ||| S:1350 E:1353 ||| IN
Akt ||| S:1353 E:1356 ||| NNP
,  ||| S:1356 E:1358 ||| ,
reduced  ||| S:1358 E:1366 ||| VBD
the  ||| S:1366 E:1370 ||| DT
phosphorylation  ||| S:1370 E:1386 ||| NN
of  ||| S:1386 E:1389 ||| IN
Bad ||| S:1389 E:1392 ||| NNP
,  ||| S:1392 E:1394 ||| ,
decreased  ||| S:1394 E:1404 ||| VBD
the  ||| S:1404 E:1408 ||| DT
expression  ||| S:1408 E:1419 ||| NN
of  ||| S:1419 E:1422 ||| IN
Bcl‑2 ||| S:1422 E:1427 ||| NNP
,  ||| S:1427 E:1429 ||| ,
increased  ||| S:1429 E:1439 ||| VBD
the  ||| S:1439 E:1443 ||| DT
expression  ||| S:1443 E:1454 ||| NN
of  ||| S:1454 E:1457 ||| IN
Bax  ||| S:1457 E:1461 ||| NNP
and  ||| S:1461 E:1465 ||| CC
the  ||| S:1465 E:1469 ||| DT
activation  ||| S:1469 E:1480 ||| NN
of  ||| S:1480 E:1483 ||| IN
caspase‑3 in  ||| S:1483 E:1496 ||| CD
H9c2 cells ||| S:1496 E:1506 ||| CD
.  ||| S:1506 E:1508 ||| .
GLP‑1 reversed  ||| S:1508 E:1523 ||| CD
the  ||| S:1523 E:1527 ||| DT
above  ||| S:1527 E:1533 ||| JJ
changes  ||| S:1533 E:1541 ||| NNS
induced  ||| S:1541 E:1549 ||| VBN
by  ||| S:1549 E:1552 ||| IN
AOPPs  ||| S:1552 E:1558 ||| JJ
and  ||| S:1558 E:1562 ||| CC
the  ||| S:1562 E:1566 ||| DT
protective  ||| S:1566 E:1577 ||| JJ
effects  ||| S:1577 E:1585 ||| NNS
of  ||| S:1585 E:1588 ||| IN
GLP‑1 were  ||| S:1588 E:1599 ||| NNP
abolished  ||| S:1599 E:1609 ||| VBD
by  ||| S:1609 E:1612 ||| IN
the  ||| S:1612 E:1616 ||| DT
PI3K  ||| S:1616 E:1621 ||| JJ
inhibitor ||| S:1621 E:1630 ||| NN
,  ||| S:1630 E:1632 ||| ,
LY294002 ||| S:1632 E:1640 ||| NNP
.  ||| S:1640 E:1642 ||| .
In  ||| S:1642 E:1645 ||| IN
conclusion ||| S:1645 E:1655 ||| NN
,  ||| S:1655 E:1657 ||| ,
the  ||| S:1657 E:1661 ||| DT
present  ||| S:1661 E:1669 ||| JJ
data  ||| S:1669 E:1674 ||| NNS
suggested  ||| S:1674 E:1684 ||| VBD
that  ||| S:1684 E:1689 ||| IN
GLP‑1 protected  ||| S:1689 E:1705 ||| CD
cardiomyocytes  ||| S:1705 E:1720 ||| NN
against  ||| S:1720 E:1728 ||| IN
AOPP‑induced  ||| S:1728 E:1741 ||| CD
apoptosis ||| S:1741 E:1750 ||| NN
,  ||| S:1750 E:1752 ||| ,
predominantly  ||| S:1752 E:1766 ||| RB
via  ||| S:1766 E:1770 ||| IN
the  ||| S:1770 E:1774 ||| DT
PI3K ||| S:1774 E:1778 ||| NNP
/ ||| S:1778 E:1779 ||| NNP
Akt ||| S:1779 E:1782 ||| NNP
/ ||| S:1782 E:1783 ||| NNP
Bad  ||| S:1783 E:1787 ||| NNP
pathway ||| S:1787 E:1794 ||| NN
.  ||| S:1794 E:1796 ||| .
These  ||| S:1796 E:1802 ||| DT
results  ||| S:1802 E:1810 ||| NNS
provided  ||| S:1810 E:1819 ||| VBD
a  ||| S:1819 E:1821 ||| DT
conceivable  ||| S:1821 E:1833 ||| JJ
mechanism  ||| S:1833 E:1843 ||| NN
for  ||| S:1843 E:1847 ||| IN
the  ||| S:1847 E:1851 ||| DT
development  ||| S:1851 E:1863 ||| NN
of  ||| S:1863 E:1866 ||| IN
diabetic  ||| S:1866 E:1875 ||| JJ
cardiomyopathy  ||| S:1875 E:1890 ||| NN
and  ||| S:1890 E:1894 ||| CC
rendered  ||| S:1894 E:1903 ||| VBD
a  ||| S:1903 E:1905 ||| DT
novel  ||| S:1905 E:1911 ||| NN
application  ||| S:1911 E:1923 ||| NN
of  ||| S:1923 E:1926 ||| IN
GLP‑1 exerting  ||| S:1926 E:1941 ||| CD
favorable  ||| S:1941 E:1951 ||| JJ
cardiac  ||| S:1951 E:1959 ||| JJ
effects  ||| S:1959 E:1967 ||| NNS
for  ||| S:1967 E:1971 ||| IN
the  ||| S:1971 E:1975 ||| DT
treatment  ||| S:1975 E:1985 ||| NN
of  ||| S:1985 E:1988 ||| IN
diabetic  ||| S:1988 E:1997 ||| JJ
cardiomyopathy ||| S:1997 E:2011 ||| NN
.  ||| S:2011 E:2013 ||| .
